Routine use of approximately 60 Gy once-daily thoracic irradiation for patients with limited-stage small-cell lung cancer

International Journal of Radiation Oncology Biology Physics

Volumn 56, Issue 2, 2003, Pages 355-359

  Miller, Keith L ^a   Marks, Lawrence B ^a   Sibley, Gregory S ^b   Clough, Robert W ^a   Garst, Jennifer L ^a   Crawford, Jeffrey ^a   Shafman, Timothy D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b Sibley Hospital   (United States)

Author keywords

Dose escalation; Radiotherapy; Small cell lung cancer

Indexed keywords

IRRADIATION; TOXICITY; TUMORS;

THORACIC IRRADIATION (RT);

ONCOLOGY;

ANTIBIOTIC AGENT; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; PACLITAXEL; PLATINUM DERIVATIVE; STEROID;

ADULT; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER SURVIVAL; ESOPHAGITIS; EYE TOXICITY; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; FRACTIONATION; HUMAN; INFECTION; LEUKEMIA; LUNG SMALL CELL CANCER; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MORBIDITY; MYELOID LEUKEMIA; PERIPHERAL NEUROPATHY; PNEUMONIA; PRIORITY JOURNAL; PROGNOSIS; PROPHYLAXIS; RADIATION DOSE; RETINA; RETINOPATHY; RETROSPECTIVE STUDY; SEPSIS; STATISTICAL ANALYSIS; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME;

EID: 0037963322     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(02)04493-0     Document Type: Article

References (27)

1. Greenlee R.T., Hill-Harmon M.B., Murray T., et al. Cancer statistics. CA Cancer J Clin. 51:2001;15-36.
2. Turrisi A.T., Kim K., Blum R., et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 340:1999;265-271.
3. Murray N., Coy P., Pater J.L., et al. The importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. J Clin Oncol. 11:1993;336-344.
4. Jeremic B., Shibamoto Y., Acimovic L., et al. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer A randomized study . J Clin Oncol. 15:1997;893-900.
5. Tsukada H, Yokoyama A, Goto K, et al. Concurrent versus sequential radiotherapy for small cell lung cancer. Semin Oncol 2001;28(2 Suppl. 4):23-26.
6. Papac R.J., Son Y., Bien R., et al. Improved local control of thoracic disease in small cell lung cancer with higher dose thoracic irradiation and cyclic chemotherapy. Int J Radiat Oncol Biol Phys. 13:1987;993-998.
7. Pignon J.P., Arriagada R., Ihde D.C., et al. A meta-analysis of thoracic radiotherapy for small-cell lung cancer. N Engl J Med. 327:1992;1618-1624.
8. Warde P., Payne D. Does thoracic radiation therapy improve survival and local control in limited stage small cell lung cancer? A meta-analysis. J Clin Oncol. 10:1992;890-895.
9. Choi N.C., Herndon J.E., Rosenman J., et al. Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. J Clin Oncol. 16:1998;3528-3536.
10. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 53:1958;457-481.
11. Cox D.R. Regression models and life tables. J Roy Stat Soc Series B. 34:1972;187-220.
12. Trotti A., Byhardt R., Stetz J., et al. Common Toxicity Criteria: version 2.0, an improved reference to grading the acute effects of cancer treatment: Impact on radiotherapy. Int J Radiat Oncol Biol Phys. 47:2000;3-47.
13. Miller A.B., Fox W., Tall R. Five-year follow-up of the Medical Research Council comparative trial of surgery and radiotherapy for the primary treatment of small-celled or oat-celled carcinoma of the bronchus. Lancet. 2:1969;501-505.
14. Perez C.A., Einhorn L., Oldham R.K., et al. Randomized trial of radiotherapy to the thorax in limited small cell carcinoma of the lung treated with multiagent chemotherapy and elective brain irradiation Preliminary report . J Clin Oncol. 2:1984;1200-1208.
15. Bunn P.A., Ihde D.C. Small cell bronchogenic carcinoma: A review of therapeutic results. Livingston R.B. Lung cancer I. 1981;169-208 Marinus Nijhoff, The Hague.
16. Perry M.C., Eaton W.L., Propert K.J., et al. Chemotherapy with or without RT in limited stage small cell lung cancer. N Engl J Med. 316:1987;912-917.
17. Gelman R., Gelber R., Henderson I.C., et al. Improved methodology for analyzing local and distant recurrence. J Clin Oncol. 8:1990;548-555.
18. Auperin A., Arriagada R., Pignon J.P., et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. N Engl J Med. 341:1999;476-484.
19. Choi N.C., Herndon J., Rosenman J., et al. Long term survival data from CALGB 8837: Radiation dose escalation and concurrent chemotherapy (CT) in limited stage small cell lung cancer (LD-SCLC). Possible radiation dose-survival relationship. Proc ASCO. 21:2002;298a.
20. Bogart JA, Herndon JE, Lyss AP, et al. 70 Gy thoracic radiotherapy (TRT) is feasible concurrent with chemotherapy for limited stage small cell lung cancer (L-SCLC): Preliminary analysis of a CALGB phase II trial. Int J Radiat Oncol Biol Phys2002;54(2 Suppl.):103a.
21. Marks L.B. Dosimetric predictors of radiation-induced lung injury. Int J Radiat Oncol Biol Phys. 54:2002;313-316.
22. Kwa S.L., Lebesque J.V., Theuws J.C., et al. Radiation pneumonitis as a function of mean lung dose An analysis of pooled data of 540 patients . Int J Radiat Oncol Biol Phys. 42:1998;1-9.
23. Maguire P.D., Sibley G.S., Zhou S.M., et al. Clinical and dosimetric predictors of radiation-induced esophageal toxicity. Int J Radiat Oncol Biol Phys. 45:1999;97-103.
24. Bradley J, Deasy J, Bentzen SM, et al. Irradiated esophageal surface area predicts for esophagitis in patients treated for non-small cell carcinoma of the lung. Int J Radiat Oncol Biol Phys 2002;54(2 Suppl.):105a.
25. Komaki R, Lee JS, Kaplan B, et al. Randomized phase III study of chemoradiation with or without amifostine for patients with favorable performance status inoperable stage II-III non-small cell lung cancer: Preliminary results. Semin Radiat Oncol 2002;12(1 Suppl. 1):46-49.
26. Antonadou D., Coliarakis N., Synodinou M., et al. Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer. Int J Radiat Oncol Biol Phys. 51:2002;915-922.
27. Giraud P, Rosenzweig KE, Yorke E, et al. Radiotherapy for lung cancer: Can IMRT decrease the risk of esophagitis? Int J Radiat Oncol Biol Phys2001;51(3 Suppl. 1):355a.